Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

被引:653
作者
Glimelius, B
Hoffman, K
Sjoden, PO
Jacobsson, G
Sellstrom, H
Enander, LK
Linne, T
Svensson, C
机构
[1] UNIV UPPSALA,DEPT SURG,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA,CTR CARING SCI,S-75185 UPPSALA,SWEDEN
[3] SJUKHUSET,DEPT SURG,SAFFLE,SWEDEN
[4] CENT SJUKHUSET,DEPT SURG,KARLSTAD,SWEDEN
[5] CENT SJUKHUSET,DEPT ONCOL,KARLSTAD,SWEDEN
[6] HUDDINGE UNIV HOSP,DEPT ONCOL,STOCKHOLM,SWEDEN
关键词
biliary cancer; chemotherapy; palliation; pancreatic cancer; randomized study;
D O I
10.1093/oxfordjournals.annonc.a010676
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In certain patients with pancreatic and biliary cancer, chemotherapy may relieve tumour-related symptoms, improve quality of life and possibly prolong survival. The extent of these improvements is not completely known in spite of the extensive use of this treatment modality. The aim of this study was to estimate any gain in the quantity and quality of life produced by chemotherapy in patients with pancreatic and biliary cancer. Patients and methods: Between January 1991 and February 1995, 90 eligible patients with pancreatic or biliary cancer were randomized to either chemotherapy in addition to best supportive care or to best supportive care. Chemotherapy was allowed in the latter group if the supportive measures did not lead to palliation. Chemotherapy was either sequential 5-fluorouracil/leucovorin combined with etoposide (FELv) or, in elderly and poor performance patients, the same regimen without etoposide (FLv). Quality of life was evaluated with the EORTC-QLQ-C30 instrument. Results: Mean scale scores in the QLQ-C30 improved more often/deteriorated less frequently in the chemotherapy group than in the best supportive care group. More patients in the chemotherapy group (36%, 17/49) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (10%, 4/41, P< 0.01). Overall survival was significantly longer in the chemotherapy group (median 6 vs. 2.5 months, P < 0.01). Also, the quality-adjusted survival time was longer for patients randomized to chemotherapy (median 4 vs. 1 months, P< 0.01). The effects were seen both in pancreatic and biliary cancer. Conclusions: The results show that chemotherapy can add to both quantity and quality of life in advanced pancreatic and biliary cancer. The number of patients who benefit from treatment is, however, still Limited; for this reason careful selection before, and close monitoring during, treatment are necessary.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 53 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   A CONTROLLED TRIAL OF COMBINATION CHEMOTHERAPY WITH 5-FU AND BCNU IN PANCREATIC-CANCER [J].
ANDERSEN, JR ;
FRIISMOLLER, A ;
HANCKE, S ;
RODER, O ;
STEEN, J ;
BADEN, H .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1981, 16 (08) :973-975
[3]   TREATMENT OF UNRESECTABLE PANCREATIC-CARCINOMA WITH 5-FLUOROURACIL, VINCRISTINE, AND CCNU [J].
ANDRENSANDBERG, A ;
HOLMBERG, JT ;
IHSE, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1983, 18 (05) :609-612
[4]  
[Anonymous], 1992, J CLIN ONCOL
[5]   AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP PHASE-II STUDY OF SINGLE-AGENT DHAD, VP-16, ACLACINOMYCIN, OR SPIROGERMANIUM IN METASTATIC PANCREATIC-CANCER [J].
ASBURY, RF ;
CNAAN, A ;
JOHNSON, L ;
HARRIS, J ;
ZAENTZ, SD ;
HALLER, DG .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (02) :166-169
[6]  
*CAR PROGR, 1990, CAR CANC PAT
[7]  
*CONS STAT, 1990, CYT DRUG TREATM ADV
[8]   LACK OF EFFICACY OF HIGH-DOSE LEUCOVORIN AND FLUOROURACIL IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA [J].
CROWN, J ;
CASPER, ES ;
BOTET, J ;
MURRAY, P ;
KELSEN, DP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1682-1686
[9]  
CULLINAN S, 1990, CANCER, V65, P2207, DOI 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO
[10]  
2-Y